News List
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
2020-11-03
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
2020-10-18
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
2020-09-28
Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
2020-09-10
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
2020-08-21
Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September
2020-07-29
Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ
Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
2020-07-06
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,
Announcement on the extension of CPHI North America 2020 in September
2020-06-19
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
2020-06-17
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
The first c-Met inhibitor approved by the FDA to market
2020-05-18
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien